Voloridge Investment Management LLC Has $9.40 Million Position in GlaxoSmithKline plc (NYSE:GSK)

Voloridge Investment Management LLC raised its stake in GlaxoSmithKline plc (NYSE:GSK) by 445.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 234,897 shares of the pharmaceutical company’s stock after acquiring an additional 191,830 shares during the period. Voloridge Investment Management LLC’s holdings in GlaxoSmithKline were worth $9,401,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. 10 15 Associates Inc. raised its holdings in GlaxoSmithKline by 2.4% in the 2nd quarter. 10 15 Associates Inc. now owns 314,002 shares of the pharmaceutical company’s stock valued at $12,566,000 after acquiring an additional 7,266 shares in the last quarter. Claraphi Advisory Network LLC increased its stake in shares of GlaxoSmithKline by 10.0% in the 2nd quarter. Claraphi Advisory Network LLC now owns 7,811 shares of the pharmaceutical company’s stock valued at $313,000 after purchasing an additional 711 shares during the last quarter. Ingalls & Snyder LLC increased its stake in shares of GlaxoSmithKline by 0.5% in the 2nd quarter. Ingalls & Snyder LLC now owns 69,497 shares of the pharmaceutical company’s stock valued at $2,781,000 after purchasing an additional 375 shares during the last quarter. Sphera Funds Management LTD. increased its stake in shares of GlaxoSmithKline by 38.7% in the 1st quarter. Sphera Funds Management LTD. now owns 430,000 shares of the pharmaceutical company’s stock valued at $17,970,000 after purchasing an additional 120,000 shares during the last quarter. Finally, First Trust Advisors LP increased its stake in shares of GlaxoSmithKline by 14.6% in the 1st quarter. First Trust Advisors LP now owns 714,614 shares of the pharmaceutical company’s stock valued at $29,864,000 after purchasing an additional 90,928 shares during the last quarter. 11.12% of the stock is owned by hedge funds and other institutional investors.

Several equities analysts have recently issued reports on the company. Societe Generale upgraded GlaxoSmithKline from a “sell” rating to a “buy” rating in a research note on Tuesday, September 3rd. ValuEngine lowered GlaxoSmithKline from a “hold” rating to a “sell” rating in a research note on Tuesday, September 10th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of GlaxoSmithKline in a research note on Tuesday, August 13th. Morgan Stanley reiterated an “underweight” rating on shares of GlaxoSmithKline in a research note on Monday, June 17th. Finally, Cowen reiterated a “hold” rating and issued a $45.00 price target on shares of GlaxoSmithKline in a research note on Monday, June 10th. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and three have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $41.79.



In other news, Director Plc Glaxosmithkline acquired 177,777 shares of GlaxoSmithKline stock in a transaction that occurred on Tuesday, September 10th. The shares were acquired at an average price of $45.00 per share, for a total transaction of $7,999,965.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 10.00% of the company’s stock.

Shares of GSK traded down $0.65 during midday trading on Wednesday, hitting $41.42. The company’s stock had a trading volume of 75,125 shares, compared to its average volume of 1,976,847. The stock has a market capitalization of $103.54 billion, a price-to-earnings ratio of 13.11, a price-to-earnings-growth ratio of 2.00 and a beta of 0.70. GlaxoSmithKline plc has a one year low of $36.41 and a one year high of $42.49. The company has a quick ratio of 0.48, a current ratio of 0.71 and a debt-to-equity ratio of 7.86. The company’s fifty day simple moving average is $41.09 and its two-hundred day simple moving average is $40.63.

GlaxoSmithKline (NYSE:GSK) last issued its quarterly earnings data on Wednesday, July 24th. The pharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.14. The business had revenue of $10.04 billion for the quarter, compared to analyst estimates of $9.55 billion. GlaxoSmithKline had a return on equity of 175.45% and a net margin of 13.84%. On average, research analysts predict that GlaxoSmithKline plc will post 2.96 earnings per share for the current year.

GlaxoSmithKline Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Recommended Story: How is the Producer Price Index calculated?

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.